Cargando…
Immune Checkpoint Inhibitors in Lung Cancer: Role of Biomarkers and Combination Therapies
Lung cancer is the leading cause of cancer-related death worldwide, with a poor prognosis. Despite aggressive treatment, progression-free survival (PFS) and overall survival are limited. Recently, various kinds of immune checkpoint inhibitors (ICIs) have emerged for several cancers, targeting PD1, P...
Autores principales: | Maung, Tun Zan, Ergin, Huseyin Ekin, Javed, Mehwish, Inga, Evelyn E, Khan, Safeera |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292688/ https://www.ncbi.nlm.nih.gov/pubmed/32542150 http://dx.doi.org/10.7759/cureus.8095 |
Ejemplares similares
-
HIV, Antiretroviral Therapy and Metabolic Alterations: A Review
por: Ergin, Huseyin Ekin, et al.
Publicado: (2020) -
Do COVID-19 and SARS Gene Complexities and Variations Help Overcome the Knowledge Gap?
por: Javed, Mehwish, et al.
Publicado: (2020) -
Immune Checkpoint Inhibitor-Induced Colitis Presenting As Lymphocytic Colitis
por: Khan, Jaffar, et al.
Publicado: (2021) -
Rituximab for Immune Checkpoint Inhibitor Myasthenia Gravis
por: Verma, Neha, et al.
Publicado: (2021) -
Immune Checkpoint Inhibitor-Induced Lymphocytic Esophagitis
por: Amin, Shefali, et al.
Publicado: (2023)